Search the Newsreel

Wabtec $WAB Shares Sold by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. reduced its stake in Wabtec (NYSE:WAB) by 4.4% in the second quarter, selling 5,222 shares and retaining 112,374 shares valued at $30.3 million. Despite this, institutional investors collectively own 91.69% of the company, with several major firms increasing their …

First Majestic Silver (AG) Stock Price, News & Analysis $AG

OranjeBTC (OBTC3) reduz prejuízo gerencial e melhora métricas de Bitcoin Treasury no 2T26

Why Vestis (VSTS) Stock Is Trading Up Today

Vestis (VSTS) stock saw a 2.3% jump after reporting mixed fiscal third-quarter results. While revenue of $661.7 million missed analyst estimates, the company's profit of $0.08 per share significantly beat forecasts, and adjusted EBITDA also surpassed expectations. Investors, however, initially focused on the revenue …

WAB Maintained by Citigroup -- Price Target Raised to $341

Citigroup has maintained a "Buy" rating for Westinghouse Air Brake Technologies Corp (WAB) and increased its price target to $341 from $311. Despite this positive analyst outlook, WAB is currently trading at $297.98, which GuruFocus indicates is 32.1% overvalued compared to its GF Value™ …

$Destiny Tech100 (DXYZ.US)$ Decide for yourself whether to sell[Shy](SPCX once rose to 73 before its IPO) NFA

An investor shared a post on the Moomoo Community regarding Destiny Tech100 (DXYZ.US), suggesting others decide whether to sell their shares. The post referenced SPCX's past performance, noting it rose to 73 before its IPO. This is presented as "NFA" (Not Financial Advice).

Verändert die von Zacks angehobene Wachstumsprognose die Investitionsargumente für Westinghouse Air Brake Technologies (WAB)?

¿Está la revisión al alza de las perspectivas de crecimiento de Zacks redefiniendo el argumento de inversión a favor de Westinghouse Air Brake Technologies (WAB)?

Why First Majestic Silver (TSX:AG) Is Up 8.1% After Strong Q2 Profits, Dividend Cut And Buybacks

First Majestic Silver (TSX:AG) saw an 8.1% stock increase following strong Q2 2026 results, reporting sales of US$415.5 million and net income of US$109.43 million. Despite a dividend cut to US$0.0152 per share, the company confirmed share repurchases worth CA$35.82 million, indicating a strategic …

Is Zacks’ Upgraded Growth View Reshaping The Investment Case For Westinghouse Air Brake Technologies (WAB)?

Zacks has highlighted Westinghouse Air Brake Technologies (WAB) due to its strong growth profile, including a top Zacks Rank and projected earnings and sales growth exceeding industry averages. This upgraded outlook, supported by positive earnings revisions and strategic contracts like the Union Pacific locomotive …

Prestige Consumer Healthcare (PBH) Bets Big On M&A, But Can Clear Eyes Recover?

Prestige Consumer Healthcare (NYSE:PBH) closed two acquisitions within three weeks this summer, adding roughly $240 million in annualized revenue to a portfolio anchored by Dramamine and Compound W. The first quarter fiscal 2027 earnings call, held August 6, showed a company beating its own …

Celestica Inc Stock (CLS) Moved Up by 7.15% on Aug 13: Drivers Behind the Movement

Celestica Inc (CLS) stock rose by 7.15% on August 13th, outperforming its sector. This surge was primarily driven by strategic capital injection from a recent equity offering, strong operational execution with upgraded guidance, and favorable institutional and analyst commentary highlighting its crucial role in …

Celestica Inc. (CLS) awards 190 D-RSUs to board director Colpitts

Celestica Inc. director Christopher W. Colpitts was granted 190 Director Restricted Share Units (D-RSUs) on August 11, 2026, as part of his equity-based compensation. These D-RSUs vest on May 20, 2027, bringing his directly held D-RSU balance to 1,000 units. Each D-RSU represents a …

Vestis (VSTS) Upgraded to Buy: What Does It Mean for the Stock?

Vestis (VSTS) has received an upgrade to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's earnings, which could lead to increased buying pressure and a rise in its stock …

Vestis (NYSE:VSTS) Price Target Raised to $13.00

JPMorgan Chase & Co. has raised its price target for Vestis (NYSE:VSTS) to $13.00 from $11.00, though it maintains an "underweight" rating on the stock, suggesting a potential downside. Despite the firm's cautious outlook, Vestis recently surpassed its quarterly EPS estimates, reporting $0.18 against …

VSTS Maintained by JP Morgan -- Price Target Raised to $13.00

JP Morgan has maintained an 'Underweight' rating on Vestis Corp (VSTS) but increased its price target from $11.00 to $13.00. Despite the raised target, the stock is considered overvalued by 21.6% according to its GF Value™ of $11.57 compared to its current price of …

LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10

LifeSci Capital analyst Francois Brisebois has reaffirmed a Buy rating for Aquestive Therapeutics (AQST.US), maintaining a target price of $10. According to TipRanks data, Brisebois has a 43.0% success rate and a 6.3% average return over the past year. This report highlights the analyst's …

First Majestic Silver Corp. (TSX:AG) Dividend Outlook: Assessing Silver Exposure, Cash Flow Strength and Distribution Sustainability

Handelsbanken Fonder AB Sells 51,753 Shares of Wabtec $WAB

Handelsbanken Fonder AB reduced its stake in Wabtec (NYSE:WAB) by 41.5% in the second quarter, selling 51,753 shares and retaining 72,898 shares valued at $19.7 million. Despite this sale, institutional investors collectively hold 91.69% of the company, and analysts maintain a "Moderate Buy" rating …

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts

Aquestive Therapeutics (NASDAQ:AQST) has received an average "Buy" rating from analysts, with a consensus 12-month price target of $8.50. Despite exceeding second-quarter revenue expectations, the company reported a larger-than-expected loss per share and issued full-year revenue guidance below analyst consensus. Insider selling and institutional …

Vestis (VSTS) Reaffirmed Guidance And Returned To Profit, Is The Stock Still Undervalued?

Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission

Aquestive Therapeutics (AQST) stock experienced a 4% dip despite positive Q2 results showing increased liquidity and reaffirmed revenue guidance. The company is nearing resubmission of its Anaphylm New Drug Application, with management addressing FDA concerns. However, ongoing adjusted EBITDA losses and the dependence on …

Hapvida (HAPV3) vê lucro desabar 95,8% no 2T26

Hain Celestial (HAIN) sees 3.5% beneficial stake reported by Charles Schwab

Charles Schwab Investment Management Inc. has filed an amended Schedule 13G, reporting a 3.5% beneficial ownership stake in Hain Celestial Group Inc. As of June 30, 2026, the firm holds 3,162,966 shares with sole voting and dispositive power. This filing classifies their position as …

Nokia, Celestica, and Applied Optoelectronics Rally After Lumentum Sparks Broad Optics Rally

Quick Read Lumentum's 109% revenue surge and blowout EPS beat dragged Nokia and Celestica each 9% higher in a broad optical sector sympathy rally. Ciena jumped 11% and AAOI added 3% atop a 296% year-to-date gain as the market re-priced AI-driven optical demand across …

Celestica (NYSE:CLS) Trading 9.3% Higher - Here's What Happened

Celestica (NYSE:CLS) shares surged 9.3% to $339.19 on Wednesday with high trading volume, following better-than-expected quarterly earnings and revenue. Analysts maintain a "Moderate Buy" rating with an average price target of $438.86, and several firms recently increased their price targets. Despite the positive performance, …

Celestica Inc (CLS) director David Reeder granted 133 new D-RSUs

Celestica Inc. director David Reeder was granted 133 Director Restricted Share Units (D-RSUs) on August 11, 2026, as part of an equity compensation. These D-RSUs vest on May 20, 2027, and entitle Reeder to either one common share or an equivalent cash value per …

Celestica Inc (CLS) awards 203 director restricted share units to Francoise Colpron

Celestica Inc (CLS) director Francoise Colpron was granted 203 Director Restricted Share Units (D-RSUs) on August 11, 2026. These D-RSUs represent a contingent right to receive one common share or an equivalent cash value upon settlement and will vest on May 20, 2027. Following …

Bullish Two Hundred Day Moving Average Cross - CLS

In trading on Wednesday, shares of Celestica Inc (Symbol: CLS) crossed above their 200 day moving average of $329.38, changing hands as high as $339.74 per share. Celestica Inc shares are currently trading up about 8.2% on the day. The chart below shows the …

Vestis Corp officers probed for possible breach of duties to shareholders

Halper Sadeh LLC is investigating whether officers and directors of Vestis Corporation breached their fiduciary duties to shareholders. The law firm is offering free consultations and operates on a contingent fee basis, encouraging long-term stockholders to act promptly due to potential time limitations. If …

Celestica Stock Leads 3 AI Infrastructure Picks With Strong Cash Generation

Aquestive Therapeutics Releases Q2 2026 Financial Results

Aquestive Therapeutics (AQST) reported a Q2 2026 diluted loss per share of $0.18, exceeding the expected loss of $0.11, with total revenue reaching $13.8 million, a 38.0% increase year-over-year. The company's net loss for the quarter was $22.9 million, and it ended with $98.5 …

Hain Celestial (HAIN): AQR Capital discloses 5.39% ownership stake in 13G filing

AQR Capital Management, LLC and its parent, AQR Capital Management Holdings, LLC, have filed a Schedule 13G disclosing a 5.39% beneficial ownership stake in Hain Celestial Group, Inc. As of June 30, 2026, they beneficially owned 4,867,461 shares of common stock. Both entities report …

Aquestive Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AQST) 2026-08-12

Aquestive Therapeutics, Inc. (AQST) published its Q2 2026 earnings call presentation on August 12, 2026. The company reported an EPS of -$0.07, beating estimates by $0.05, and revenue of $13.82 million, a 38.15% year-over-year increase, beating estimates by $2.26 million. This presentation provides details …

First Majestic Silver Aktie: 0,21 Dollar EPS verfehlt Konsens

Aquestive Therapeutics (NASDAQ:AQST) Shares Gap Down Following Weak Earnings